 Jeanne Benoit
Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Limbic Encephalitis | 1 | 2022 | 6 | 0.800 |
Why?
| | Drug Carriers | 2 | 2020 | 128 | 0.700 |
Why?
| | Hyaluronic Acid | 2 | 2020 | 225 | 0.700 |
Why?
| | Neuralgia | 1 | 2022 | 133 | 0.690 |
Why?
| | Encephalitis | 1 | 2022 | 136 | 0.690 |
Why?
| | Nanocapsules | 3 | 2015 | 14 | 0.650 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 165 | 0.650 |
Why?
| | Nasal Cavity | 1 | 2018 | 52 | 0.560 |
Why?
| | Peptides | 2 | 2020 | 985 | 0.540 |
Why?
| | Staphylococcal Infections | 2 | 2018 | 400 | 0.500 |
Why?
| | Mycobacterium abscessus | 3 | 2023 | 117 | 0.490 |
Why?
| | Bacteremia | 1 | 2018 | 214 | 0.480 |
Why?
| | Mycobacterium Infections, Nontuberculous | 4 | 2023 | 363 | 0.460 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2015 | 94 | 0.450 |
Why?
| | Staphylococcus aureus | 2 | 2018 | 450 | 0.450 |
Why?
| | Nanoparticles | 1 | 2020 | 481 | 0.430 |
Why?
| | Evolution, Molecular | 1 | 2018 | 493 | 0.430 |
Why?
| | Deoxycytidine | 1 | 2015 | 179 | 0.430 |
Why?
| | Lymphatic Metastasis | 1 | 2015 | 352 | 0.420 |
Why?
| | Genomics | 1 | 2018 | 795 | 0.390 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 2129 | 0.340 |
Why?
| | Lipids | 1 | 2015 | 672 | 0.330 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 1081 | 0.250 |
Why?
| | Lung Neoplasms | 2 | 2020 | 2526 | 0.250 |
Why?
| | Hemangioma, Cavernous, Central Nervous System | 1 | 2025 | 8 | 0.240 |
Why?
| | Drug Resistant Epilepsy | 1 | 2025 | 102 | 0.210 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2023 | 28 | 0.200 |
Why?
| | Contactins | 1 | 2022 | 2 | 0.200 |
Why?
| | Asthenia | 1 | 2022 | 3 | 0.200 |
Why?
| | Demyelinating Diseases | 1 | 2023 | 85 | 0.200 |
Why?
| | Nerve Net | 1 | 2025 | 256 | 0.190 |
Why?
| | Mycobacterium | 1 | 2023 | 108 | 0.190 |
Why?
| | Muromegalovirus | 1 | 2021 | 23 | 0.180 |
Why?
| | Tissue Distribution | 2 | 2020 | 332 | 0.180 |
Why?
| | Drug Compounding | 2 | 2020 | 101 | 0.180 |
Why?
| | Cystic Fibrosis | 2 | 2021 | 1114 | 0.170 |
Why?
| | Emulsions | 2 | 2019 | 53 | 0.170 |
Why?
| | Genome, Bacterial | 1 | 2021 | 142 | 0.170 |
Why?
| | HT29 Cells | 1 | 2020 | 41 | 0.170 |
Why?
| | A549 Cells | 1 | 2020 | 66 | 0.160 |
Why?
| | DNA, Bacterial | 1 | 2021 | 337 | 0.160 |
Why?
| | Injections, Intravenous | 1 | 2020 | 206 | 0.160 |
Why?
| | Drug Stability | 1 | 2020 | 167 | 0.160 |
Why?
| | Cytomegalovirus Infections | 1 | 2021 | 192 | 0.160 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 278 | 0.160 |
Why?
| | Peritoneal Neoplasms | 1 | 2020 | 93 | 0.160 |
Why?
| | Brain Diseases, Metabolic, Inborn | 1 | 2019 | 4 | 0.160 |
Why?
| | Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2019 | 6 | 0.160 |
Why?
| | Seizures | 1 | 2022 | 426 | 0.150 |
Why?
| | Creatine | 1 | 2019 | 57 | 0.150 |
Why?
| | Nerve Tissue Proteins | 1 | 2022 | 596 | 0.150 |
Why?
| | Fucosyltransferases | 1 | 2018 | 33 | 0.150 |
Why?
| | Cisplatin | 1 | 2020 | 320 | 0.140 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 449 | 0.140 |
Why?
| | Membrane Transport Proteins | 1 | 2019 | 162 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2023 | 455 | 0.140 |
Why?
| | Colonic Neoplasms | 1 | 2020 | 258 | 0.140 |
Why?
| | Lymphocyte Activation | 1 | 2021 | 1142 | 0.130 |
Why?
| | Genetic Variation | 2 | 2021 | 991 | 0.130 |
Why?
| | Female | 12 | 2025 | 73304 | 0.130 |
Why?
| | Cell Survival | 1 | 2020 | 1120 | 0.130 |
Why?
| | Otitis Media | 1 | 2018 | 165 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2022 | 1164 | 0.120 |
Why?
| | Drug Delivery Systems | 2 | 2019 | 365 | 0.120 |
Why?
| | Mediastinum | 1 | 2015 | 23 | 0.120 |
Why?
| | Nose | 1 | 2015 | 67 | 0.120 |
Why?
| | Autoantibodies | 1 | 2022 | 1496 | 0.110 |
Why?
| | Tumor Microenvironment | 1 | 2019 | 674 | 0.110 |
Why?
| | Glioma | 1 | 2019 | 395 | 0.110 |
Why?
| | Humans | 16 | 2025 | 137585 | 0.110 |
Why?
| | Polyglutamic Acid | 1 | 2014 | 3 | 0.110 |
Why?
| | Ovarian Neoplasms | 1 | 2020 | 565 | 0.110 |
Why?
| | Mice, SCID | 1 | 2015 | 367 | 0.110 |
Why?
| | Middle Aged | 5 | 2025 | 33479 | 0.110 |
Why?
| | Taxoids | 1 | 2014 | 102 | 0.110 |
Why?
| | Animals | 8 | 2021 | 36940 | 0.100 |
Why?
| | Brain | 1 | 2025 | 2668 | 0.100 |
Why?
| | Mice, Nude | 1 | 2015 | 698 | 0.100 |
Why?
| | Mycobacterium kansasii | 1 | 2012 | 15 | 0.100 |
Why?
| | Aged, 80 and over | 3 | 2021 | 7635 | 0.100 |
Why?
| | Models, Biological | 1 | 2020 | 1783 | 0.100 |
Why?
| | Cohort Studies | 2 | 2025 | 5742 | 0.100 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 234 | 0.100 |
Why?
| | Lymph Nodes | 1 | 2015 | 491 | 0.100 |
Why?
| | Mice, Inbred C57BL | 2 | 2020 | 5757 | 0.090 |
Why?
| | Microbiota | 2 | 2018 | 762 | 0.090 |
Why?
| | Anorexia Nervosa | 1 | 2012 | 89 | 0.090 |
Why?
| | Macrophages | 1 | 2019 | 1547 | 0.090 |
Why?
| | Polyethylene Glycols | 2 | 2014 | 641 | 0.090 |
Why?
| | Hospitalization | 2 | 2018 | 2199 | 0.090 |
Why?
| | Quality of Life | 1 | 2022 | 2892 | 0.080 |
Why?
| | Male | 7 | 2025 | 67762 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1238 | 0.080 |
Why?
| | Interferon-gamma | 1 | 2012 | 789 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2025 | 15657 | 0.070 |
Why?
| | Biomimetic Materials | 1 | 2009 | 72 | 0.070 |
Why?
| | Genetic Vectors | 1 | 2009 | 319 | 0.070 |
Why?
| | Liposomes | 1 | 2009 | 223 | 0.070 |
Why?
| | Risk Factors | 2 | 2018 | 10388 | 0.060 |
Why?
| | Antitubercular Agents | 2 | 2021 | 206 | 0.060 |
Why?
| | Lung Diseases | 1 | 2012 | 767 | 0.060 |
Why?
| | Aged | 3 | 2021 | 23961 | 0.060 |
Why?
| | COS Cells | 2 | 2018 | 188 | 0.060 |
Why?
| | Mycobacterium smegmatis | 1 | 2023 | 11 | 0.050 |
Why?
| | Mice | 5 | 2021 | 17787 | 0.050 |
Why?
| | Electroencephalography | 1 | 2025 | 423 | 0.050 |
Why?
| | DNA | 1 | 2009 | 1459 | 0.050 |
Why?
| | Lung | 1 | 2015 | 4060 | 0.050 |
Why?
| | Clone Cells | 1 | 2021 | 265 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2021 | 186 | 0.040 |
Why?
| | Glycolipids | 1 | 2020 | 42 | 0.040 |
Why?
| | Nanomedicine | 1 | 2020 | 47 | 0.040 |
Why?
| | Administration, Intranasal | 1 | 2019 | 90 | 0.040 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2019 | 156 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2020 | 688 | 0.040 |
Why?
| | Ear, Middle | 1 | 2018 | 85 | 0.040 |
Why?
| | Sputum | 1 | 2020 | 311 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2019 | 307 | 0.040 |
Why?
| | Adult | 4 | 2025 | 37929 | 0.030 |
Why?
| | Exome | 1 | 2018 | 231 | 0.030 |
Why?
| | Pedigree | 1 | 2018 | 514 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2019 | 202 | 0.030 |
Why?
| | Phylogeny | 1 | 2021 | 904 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2019 | 363 | 0.030 |
Why?
| | Microglia | 1 | 2019 | 251 | 0.030 |
Why?
| | Monocytes | 1 | 2019 | 563 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 730 | 0.030 |
Why?
| | Antibiosis | 1 | 2015 | 10 | 0.030 |
Why?
| | Streptococcus mitis | 1 | 2015 | 10 | 0.030 |
Why?
| | Lactobacillus | 1 | 2015 | 29 | 0.030 |
Why?
| | Catalase | 1 | 2015 | 130 | 0.030 |
Why?
| | Carrier State | 1 | 2015 | 67 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1381 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1738 | 0.030 |
Why?
| | Adolescent | 2 | 2025 | 21513 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2021 | 2475 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 2189 | 0.030 |
Why?
| | Young Adult | 2 | 2025 | 13209 | 0.030 |
Why?
| | Delayed-Action Preparations | 1 | 2014 | 181 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2015 | 549 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2019 | 828 | 0.020 |
Why?
| | Cell Line | 1 | 2018 | 2847 | 0.020 |
Why?
| | Surface Properties | 1 | 2014 | 413 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2014 | 455 | 0.020 |
Why?
| | Ethambutol | 1 | 2012 | 26 | 0.020 |
Why?
| | Particle Size | 1 | 2014 | 394 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 1062 | 0.020 |
Why?
| | Hemolysis | 1 | 2014 | 206 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 812 | 0.020 |
Why?
| | Isoniazid | 1 | 2012 | 63 | 0.020 |
Why?
| | Rifampin | 1 | 2012 | 84 | 0.020 |
Why?
| | Antibodies, Bacterial | 1 | 2012 | 146 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 889 | 0.020 |
Why?
| | Rats | 1 | 2020 | 5647 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2014 | 872 | 0.020 |
Why?
| | Lymphocytes | 1 | 2012 | 397 | 0.020 |
Why?
| | Oleic Acids | 1 | 2009 | 11 | 0.020 |
Why?
| | Stearic Acids | 1 | 2009 | 15 | 0.020 |
Why?
| | Zymosan | 1 | 2009 | 65 | 0.020 |
Why?
| | Polymethyl Methacrylate | 1 | 2009 | 22 | 0.020 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2009 | 52 | 0.020 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2009 | 54 | 0.020 |
Why?
| | Half-Life | 1 | 2009 | 164 | 0.020 |
Why?
| | Cations | 1 | 2009 | 84 | 0.020 |
Why?
| | Phosphatidylethanolamines | 1 | 2009 | 77 | 0.020 |
Why?
| | Glycerol | 1 | 2009 | 94 | 0.020 |
Why?
| | Erythrocytes | 1 | 2014 | 700 | 0.020 |
Why?
| | Cryoelectron Microscopy | 1 | 2009 | 190 | 0.020 |
Why?
| | Mutation | 1 | 2019 | 3958 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 4149 | 0.020 |
Why?
| | Materials Testing | 1 | 2009 | 356 | 0.020 |
Why?
| | HeLa Cells | 1 | 2009 | 636 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3566 | 0.020 |
Why?
| | Triglycerides | 1 | 2009 | 524 | 0.020 |
Why?
| | United States | 1 | 2021 | 14841 | 0.010 |
Why?
| | Child | 1 | 2021 | 21935 | 0.010 |
Why?
|
|
Benoit's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|